Zacks: Analysts Anticipate Medidata Solutions Inc (MDSO) to Post $0.31 EPS
Analysts expect Medidata Solutions Inc (NASDAQ:MDSO) to report $0.31 earnings per share for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Medidata Solutions’ earnings. The highest EPS estimate is $0.38 and the lowest is $0.25. Medidata Solutions reported earnings per share of $0.33 in the same quarter last year, which would suggest a negative year-over-year growth rate of 6.1%. The business is scheduled to report its next earnings report on Thursday, February 8th.
On average, analysts expect that Medidata Solutions will report full year earnings of $1.27 per share for the current fiscal year, with EPS estimates ranging from $1.21 to $1.34. For the next fiscal year, analysts expect that the company will report earnings of $1.46 per share, with EPS estimates ranging from $1.31 to $1.61. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Medidata Solutions.
Medidata Solutions (NASDAQ:MDSO) last released its earnings results on Thursday, October 26th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.02. Medidata Solutions had a return on equity of 11.54% and a net margin of 7.84%. The business had revenue of $140.08 million for the quarter, compared to analyst estimates of $141.27 million. During the same quarter in the prior year, the company posted $0.28 earnings per share. Medidata Solutions’s revenue was up 16.7% on a year-over-year basis.
In other Medidata Solutions news, EVP Michael I. Otner sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $70.88, for a total transaction of $708,800.00. Following the transaction, the executive vice president now owns 80,674 shares of the company’s stock, valued at $5,718,173.12. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Tarek Sherif sold 200,000 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $68.76, for a total value of $13,752,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 239,010 shares of company stock worth $16,437,036. Company insiders own 5.80% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Fortaleza Asset Management Inc. acquired a new position in shares of Medidata Solutions in the third quarter valued at approximately $155,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Medidata Solutions by 10.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,186 shares of the company’s stock valued at $171,000 after purchasing an additional 208 shares during the last quarter. Polen Capital Management LLC acquired a new position in shares of Medidata Solutions in the third quarter valued at approximately $205,000. Cubist Systematic Strategies LLC acquired a new position in shares of Medidata Solutions in the second quarter valued at approximately $227,000. Finally, ETF Managers Group LLC acquired a new position in shares of Medidata Solutions in the second quarter valued at approximately $233,000. 97.52% of the stock is currently owned by institutional investors.
Shares of Medidata Solutions (NASDAQ:MDSO) opened at $65.91 on Thursday. Medidata Solutions has a twelve month low of $47.77 and a twelve month high of $85.92. The stock has a market capitalization of $3,704.67, a PE ratio of 94.16, a P/E/G ratio of 3.28 and a beta of 1.69. The company has a current ratio of 1.29, a quick ratio of 3.37 and a debt-to-equity ratio of 0.61.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.